On Retinal Gene Therapy

Overview

Journal Ophthalmologica

Publisher Karger

Specialty Ophthalmology

Date 2016 Apr 28

PMID 27119148

Citations 5

Authors

M Dominik Fischer

Affiliations

Soon will be listed here.

Abstract

Mutations in a large number of genes cause retinal degeneration and blindness with no cure currently available. Retinal gene therapy has evolved over the last decades to become a promising new treatment paradigm for these rare disorders. This article reflects on the ideas and concepts arising from basic science towards the translation of retinal gene therapy into the clinical realm. It describes the advances and present thinking on the efficacy of current clinical trials and discusses potential roadblocks and solutions for the future of retinal gene therapy.

Citing Articles

Longitudinal Evaluation of Hyper-Reflective Foci in the Retina Following Subretinal Delivery of Adeno-Associated Virus in Non-Human Primates.

Rodriguez-Bocanegra E, Wozar F, Seitz I, Reichel F, Ochakovski A, Bucher K Transl Vis Sci Technol. 2021; 10(6):15.

PMID: 34111260 PMC: 8114007. DOI: 10.1167/tvst.10.6.15.

RPE-derived exosomes rescue the photoreceptors during retina degeneration: an intraocular approach to deliver exosomes into the subretinal space.

Wang Y, Zhang Q, Yang G, Wei Y, Li M, Du E Drug Deliv. 2021; 28(1):218-228.

PMID: 33501868 PMC: 7850421. DOI: 10.1080/10717544.2020.1870584.

Intravitreal Delivery of Melatonin Is Protective Against the Photoreceptor Loss in Mice: A Potential Therapeutic Strategy for Degenerative Retinopathy.

Li C, Tian Y, Yao A, Zha X, Zhang J, Tao Y Front Pharmacol. 2020; 10:1633.

PMID: 32116667 PMC: 7028754. DOI: 10.3389/fphar.2019.01633.

Statement of the DOG, the RG, and the BVA on the therapeutic use of voretigene neparvovec (Luxturna™) in ophthalmology. English version : January 2019.

Ophthalmologe. 2019; 117(Suppl 1):16-24.

PMID: 31089806 DOI: 10.1007/s00347-019-0906-2.

[Statement of the German Society of Ophthalmology (DOG), the German Retina Society (RG) and the Professional Association of German Ophthalmologists (BVA) on the therapeutic use of voretigene neparvovec-rzyl (Luxturna™) in ophthalmology : Situation...].

Ophthalmologe. 2019; 116(6):524-533.

PMID: 31016385 DOI: 10.1007/s00347-019-0885-3.